Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections

Lancet

Volumn 352, Issue 9144, 1998, Pages 1877-1881

  Campion, Katrina ^b   Silagy, Cris A ^a   Keene, Oliver ^b   Cooper, Chris ^b   Bolton, Patrick ^b   Watts, Richard ^b   Lincoln, Port ^b   Liaw, Teng ^b   Narayan, Kam ^b   Delooze, Fred ^b  

^a FLINDERS MEDICAL CENTRE   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ZANAMIVIR;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; AUSTRALIA; BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INFLUENZA VIRUS A; INFLUENZA VIRUS B; INHALATIONAL DRUG ADMINISTRATION; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; NEW ZEALAND; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SIDE EFFECT; SINUSITIS; SOUTH AFRICA; SYMPTOM; VOMITING;

EID: 0032512327     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)10190-3     Document Type: Article

References (22)

1. 1 Dolin R. Influenza. In: Harrison's principles of internal medicine, 14th edn. USA: McGraw-Hill, 1998: 1112-16.
2. 2 Cate TR. Clinical manifestations and consequences of influenza. Am J Med 1987; 82: 15-19.
3. 3 Schoenbaum SC. Economic impact of influenza: the individual's perspective. Am J Med 1987; 82: 26-30.
4. 4 Monto AS. Influenza: quantifying morbidity and mortality. Am J Med 1987; 32: 20-25.
5. 5 Monto AS. Prospects for pandemic influenza control with currently available vaccines and antivirals. J Infect Dis 1997; 176: S32-37.
6. 6 Van Voris LP, Newell PM. Antivirals for the chemoprophylaxis and treatment of influenza. Semin Respir Infect 1992; 7: 61-70.
7. 7 Hayden FG. Amantidine and rimantadine resistance in influenza A viruses. Curr Opin Infect Dis 1994; 7: 674-77.
8. 8 Belshe RB, Burk B, Newman F, Cerruti RL, Sim IS. Resistance of influenza A virus to amantadine and rimantadine: results of one decade of surveillance. J Infect Dis 1989; 159: 430-35.
9. 9 von Itzstein M, Wu WY, Kok GB, et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993; 363: 418-23.
10. 10 Luo M, Air GM, Brouillette WJ. Design of aromatic inhibitors of influenza virus neuraminidase. J Infect Dis 1997; 165: S62-65.
11. 11 Liu C, Air GM. Selection and characterization of a neuraminidase-minus mutant of influenza virus and its rescue by cloned neuraminidase genes. Virology 1993; 194: 403-07.
12. 12 Colman PM. Neuraminidase: enzyme and antigen. In: Krug RM, ed. The influenza viruses. New York: Plenum Press, 1989: 175-218.
13. 13 Woods JM, Bethell RC, Coates JAV, et al. 4-Guanidino-2, 4-didoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob Agents Chemother 1993; 37: 1473-79.
14. 14 Hayden FG, Rollins BS, Madren LK. Anti-influenza virus activity of the neruaminidase inhibitor 4-guanidino-Neu5Ac2en in cell culture and in human respiratory epithelium. Antiviral Res 1994; 25: 123-31.
15. 15 Ryan DM, Ticehorse J, Dempsey MH, Penn CR. Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-didcoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase). Antimicrob Agents Chemother 1994; 38: 2770-75.
16. 16 Hayden FG, Treanor JJ, Betts RF, Lobo M, Esinhart JD, Hussey EK. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. JAMA 1996; 275: 295-99.
17. 17 Hayden FG, Lobo M, Hussey EK, Eason CU. Efficacy of intranasal GG167 in experimental human influenza A and B virus infection. In: Brown LE, Hampson AW, Webster RG, eds. Options for the control of influenza III. Amsterdam: Elsevier Science, 1996: 718-25.
18. 18 Hayden FG, Osterhaus ADME, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. N Engl J Med 1997; 337: 874-80.
19. 19 Lehmann EL. Nonparametrics: statistical methods based on ranks. San Francisco: Holden-Day, 1975.
20. 20 Efron B, Tibshirani RJ. An introduction to the bootstrap. New York: Chapman and Hall, 1993: 178-412.
21. 21 Barnett J, Dempsey M, Tisdale M, et al. Susceptibility monitoring of influenza virus clinical isolates to the neuraminidase inhibitor zanamivir (GG167) during phase II clinical efficacy trials: abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28-Oct 1. Canada: Toronto, 1997: 230.
22. 22 Osterhaus ADME, Tisdale M, Elliott M. A double blind randomised trial of zanamivir in the treatment of acute influenza: clinical and virological efficacy results. Final Program, Abstracts and Exhibits Addendum of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24-27. San Diego: 1998: 11.